Pfizer Inc. (NYSE:PFE) Shares Bought by Integral Investment Advisors Inc.

Integral Investment Advisors Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 15.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,513 shares of the biopharmaceutical company’s stock after buying an additional 2,649 shares during the period. Integral Investment Advisors Inc.’s holdings in Pfizer were worth $562,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of PFE. Moneta Group Investment Advisors LLC raised its holdings in shares of Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares during the period. Morgan Stanley lifted its position in shares of Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares in the last quarter. Norges Bank purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $3,150,472,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Pfizer by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after purchasing an additional 5,185,453 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on PFE. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Down 0.3 %

Shares of Pfizer stock traded down $0.07 during trading hours on Thursday, hitting $25.35. The company had a trading volume of 27,660,071 shares, compared to its average volume of 42,353,340. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.56. The company has a market cap of $143.55 billion, a P/E ratio of 70.25, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company’s 50-day moving average is $27.19 and its two-hundred day moving average is $28.76.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.14 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.